Given the pervasive activation of the EGF receptor (EGFR) signaling pathway in CRC and mCRC, the EGFR antibodies cetuximab and panitumumab are approved to treat mCRC together with the traditional chemotherapy including folinic acid, fluorouracil and irinotecan (FOLFOX) and folinic acid, fluorouracil and oxaliplatin (FOLFIRI) [3]. Here, EGFR is linked to colorectal carcinoma.